A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 15, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to participate in two virtual investor conferences this week: 2020 Cantor
Toggle Summary Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 14, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it has promoted Richard T. Kloos , M.D., to executive medical director, overseeing Veracyte’s global medical affairs in all clinical areas addressed by the company’s expanding menu of


There are currently no events to display.


Title Documents

Corporate Presentation August 2020